XBI241115P103000
- 5.38
- +2.82+110.16%
SPDR S&P Biotech ETF Newsroom
SPDR S&P Biotech ETF Options Spot-On: On November 14th, 160.61K Contracts Were Traded, With 954.71K Open Interest
On November 14th ET, $SPDR S&P Biotech ETF(XBI.US)$ had active options trading, with a total trading volume of 160.61K options for the day, of which put options accounted for 65.41% of the total
Druckenmiller's Duquesne Closes Some Media Holdings, Loads Into Regional Banks, Among Q3 Trades
Cracking The Code: Understanding Analyst Reviews For Incyte
Gilead, Vertex Initiated as New Big Biotech Buys at Citi
Incyte Analyst Ratings
InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And Β-Thalassemia
Gilead Sciences Analyst Ratings
Vertex Pharmaceuticals Analyst Ratings
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Natera Analysts Increase Their Forecasts Following Upbeat Results
10 Health Care Stocks With Whale Alerts In Today's Session
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
Market-Moving News for November 13th
Baird Maintains Outperform on Natera, Raises Price Target to $160
Natera Analyst Ratings
Viking Therapeutics To Present Data From Phase 2b VOYAGE Study Of VK2809 In Patients With Biopsy-Confirmed NASH/MASH At 75th Liver Meeting 2024
Natera Sees FY24 SG&A $775M-$825M; R&D $375M-$400M' Net Cash Inflows $50M-$75M.
Natera Sees FY24 Revenue $1.61B-$1.64B Vs $1.518B Est
Natera Q3 2024 GAAP EPS $(0.26) Beats $(0.58) Estimate, Sales $439.800M Beat $361.450M Estimate